Minerva Neurosciences, Inc. Capitalized Computer Software, Amortization
Minerva Neurosciences, Inc. (NERV) reported Capitalized Computer Software, Amortization of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedComputerSoftwareAmortization1 · last filed 2026-03-11
- Minerva Neurosciences, Inc. capitalized computer software, amortization for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. capitalized computer software, amortization for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. capitalized computer software, amortization for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. capitalized computer software, amortization for the quarter ending 2024-09-30 was $4.26K, a 33.33% decline year-over-year.
- Minerva Neurosciences, Inc. capitalized computer software, amortization for fiscal 2024 was $17.03K, a 33.33% decline from fiscal 2023.
- Minerva Neurosciences, Inc. capitalized computer software, amortization for fiscal 2023 was $25.54K, a 200.01% increase from fiscal 2022.
- Minerva Neurosciences, Inc. capitalized computer software, amortization for fiscal 2022 was $8.51K.
| Period end | Capitalized Computer Software, Amortization 3 month | Capitalized Computer Software, Amortization 6 month | Capitalized Computer Software, Amortization 9 month | Capitalized Computer Software, Amortization 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-11 | $4.26K derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $4.26K derived: sum of 3 quarters · filed 2026-03-11 | $10.64K derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.26K derived: sum of 2 quarters · filed 2026-03-11 | $10.64K derived: sum of 3 quarters · filed 2026-03-11 | $17.03K 10-K · filed 2026-03-11 |
| 2024-09-30 | $4.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $10.64K derived: sum of 2 quarters · filed 2025-11-05 | $17.03K 10-Q · filed 2025-11-05 | $23.41K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $6.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $12.77K 10-Q · filed 2025-08-14 | $19.16K derived: sum of 3 quarters · filed 2025-08-14 | $25.54K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $6.38K 10-Q · filed 2025-05-13 | $12.77K derived: sum of 2 quarters · filed 2025-05-13 | $19.16K derived: sum of 3 quarters · filed 2025-05-13 | $25.54K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $6.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $12.77K derived: sum of 2 quarters · filed 2025-02-25 | $19.16K derived: sum of 3 quarters · filed 2025-02-25 | $25.54K 10-K · filed 2025-02-25 |
| 2023-09-30 | $6.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $12.77K derived: sum of 2 quarters · filed 2024-11-05 | $19.16K 10-Q · filed 2024-11-05 | $25.54K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $6.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $12.77K 10-Q · filed 2024-08-06 | $19.16K derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | $6.38K 10-Q · filed 2024-05-01 | $12.77K derived: sum of 2 quarters · filed 2024-05-01 | ||
| 2022-12-31 | $6.38K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $8.51K 10-K · filed 2024-02-22 | ||
| 2022-09-30 | $2.13K 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |